

Signant SmartSignals® Solutions
for Atopic Dermatitis

A BETTER APPROACH FOR A BETTER ATOPIC DERMATITIS TRIAL

Atopic dermatitis is the most common inflammatory skin condition worldwide. Despite its prevalence, clinical assessments for atopic dermatitis are extremely complex. Between the various scoring scales used and the wide range of patients, consistency across a clinical study is a challenge.

STANDARDIZE RATER TRAINING

Our targeted atopic dermatology rater training standardizes clinician-reported outcome (ClinRO) scales, limits the augmentation of placebo responses, and improves assessment techniques. Designed and implemented by experienced clinician raters, Rater Training and Qualification prevents inter- and intra-rater variability from impacting your signal detection.

ELIMINATE BETWEEN-SCALE INCONSISTENCIES

Atopic dermatology trials often include multiple clinician-reported outcome scales, which can contain overlapping assessment areas such as body surface area (BSA) assessment. With approval of scale authors, Signant combined the three common scales (SCORAD, EASI, and BSA) into a single, custom assessment. Our novel implementation simplifies data collection by reducing the unnecessary need for duplicate assessments and decreasing inter-scale inconsistencies.

ASSESS DIVERSE SKIN TYPES PROPERLY

We've worked with leading dermatologists to create a unique set of reference and training images that represent the diversity of skin types required in global clinical trials.

IMPROVE IN-STUDY ENDPOINT RELIABILITY

Our centralized statistical monitoring of clinical outcome assessment data identifies outliers, patterns, inconsistencies, and potential fraud to enable proactive corrective actions. Led by expert clinicians and data scientists, our PureSignal Analytics solution provides actionable insights to mitigate risks and optimize signal detection.

ACCOMMODATE PEDIATRIC PATIENTS

Our flexible platform enables implementation of different patient-reported outcome instrument versions based on the individual's age as well as offers the caregiver access needed for younger patients.



At Signant, we've led the way in accurate and inclusive assessments. Our Signant SmartSignals® solutions continue to optimize data quality and for atopic dermatitis trials.

SIGNANT'S ATOPIC DERMATITIS EXPERIENCE BY THE NUMBERS



I - IV
PHASES



112
TRIALS



7.5k+
SITES



32k+
PATIENTS




30
COUNTRIES



51
LANGUAGES

DRIVE BETTER RESEARCH OUTCOMES WITH SIGNANT SMARTSIGNALS® SOLUTIONS

These solutions can be used individually or integrated together for a seamless, end-to-end digital experience.




eCOA

[LEARN MORE →](#)



RATER TRAINING
& QUALIFICATION

[LEARN MORE →](#)



RTSM

[LEARN MORE →](#)




PURESIGNAL
ANALYTICS

[LEARN MORE →](#)

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



[MEET THE EXPERTS →](#)